IDO1 and neoplasm: Imatinib also decreased Treg frequencies and enhanced anti-tumor immune responses to DC vaccination against imatinib-resistant BCR-ABL-negative lymphoma (42), and was subsequently shown to activate CD8+ T cells and induce Treg apoptosis in a gastrointestinal tumor model through c-KIT inhibition and diminished IDO expression (35).